East China Pharmaceuticals: The first subject in the Phase I clinical trial of the innovative drug HDM2020 in China has been dosed.

On August 13, East China Pharmaceutical announced that the Phase I clinical trial of HDM2020, developed by its wholly-owned subsidiary Hangzhou Sino-American East China Pharmaceutical Co., Ltd., for the treatment of advanced solid tumors, achieved its first successful dosing of a subject at the Sun Yat-sen University Cancer Center.